Loading patent…
AssigneeGlykos Finland Oy
InventorsJari NATUNEN, Susann TENEBERG, Karl-Anders KARLSSON, Tero SATOMAA, Annamari HEISKANEN
Estimating the term…
The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.
A pharmaceutical composition comprising a substance binding to a human tumor specific oligosaccharide sequence containing a terminal protein linked GlcNAcβ-structure or a terminal protein linked GlcNAcβ-glycan-structure for the treatment of a human cancer.
A method for diagnosing cancer or tumor in a biological sample taken from a human patient, the method comprising determining the presence in said sample of an oligosaccharide sequence which comprises a tumor specific terminal protein linked GlcNAcβ-structure or a terminal protein linked GlcNAcβ-glycan-structure.
A human anti-GlcNAc antibody obtainable by:
Dependencies are inferred from the claim text.